ELIQUIS receives European approval
The approval is based on the ADVANCE-2 and ADVANCE-3 clinical trials, part of the EXPANSE clinical trial program. ELIQUIS is an oral anticoagulant with a 12- to 24-hour
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
PinAAcle series’ configuration allows for compact design in applications like environmental regulations for drinking water, clinical usage in customer-validated applications such as screening for lead, and requirements of